(Reuters Health)—Behavior changes could potentially reduce a large part of the risk for developing gout, a U.S. study suggests. Based on data from more than 14,000 people, researchers calculated how much factors like being overweight, following a diet that isn’t heart healthy, drinking alcohol or taking diuretics contribute to high levels of uric acid—a precursor…
Lupus Treatments: Into the Future
As the 21st century unfolds, rheumatologists will most likely transition from prescribing lupus patients broad immunosuppressants to more targeted treatment approaches. But to make this happen and advance research, the challenges experienced in lupus clinical trial design must be addressed…
Updated OARSI Guideline for the Non-Surgical Management of Osteoarthritis
The recently updated Osteoarthritis Research Society International (OARSI) guideline offers comprehensive and patient-centered treatment approaches for individuals with knee, hip and polyarticular OA…
FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis
Data from two phase 3 studies were used to support the FDA’s approval of ixekizumab for adults with ankylosing spondylitis…
RheumPAC Advocates for Dept. of Defense Arthritis Research Funding
RheumPAC is the ACR’s non-partisan political action committee, which promotes the needs of rheumatology providers and patients. Advocacy efforts often focus on legislation to improve the day-to-day clinical care of rheumatology patients, such as establishing clinical exceptions to step therapy requirements and reforming the prior authorization process. In addition, the ACR and RheumPAC recognize the…
Study Says Sjögren’s Patients Have a High Specificity for a Novel Antibody
An antibody previously un-recognized in patients with Sjögren’s syndrome may shed new light on the pathophysiology of one of the most troubling and disabling symptoms in many of these patients. Investigators at Johns Hopkins University, Baltimore, found the anti-calponin 3 antibody had a high specificity for Sjögren’s syndrome, particularly among patients with neuropathies.1 “There is…
Probing the Role of Genes & Microbiome in Ankylosing Spondylitis & RA
Researchers know human leukocyte antigen (HLA) molecules affect susceptibility to disease in general, and immunological disease in particular. In the case of ankylosing spondylitis (AS), the risk is primarily associated with HLA-B27, with smaller effects from other HLA alleles. Current thinking is that AS is caused by the presence of a genetically primed host because…
Study: Screen Hospitalized Lupus Patients for Venous Thromboembolism
When patients with lupus are hospitalized, they should be screened and likely treated for venous thromboembolism, researchers of a nationwide study say. In May, ACR Open Rheumatology published results of the large retrospective study spanning several years. Researchers analyzed trends in mortality, morbidity and hospitalization from venous thromboembolism (VTE), specifically among patients diagnosed with systemic…
Study Finds Chronic Opioid Use Doubled in Rheumatoid Arthritis Patients
The prevalence of chronic opioid use among patients with rheumatoid arthritis (RA) doubled between 2002 and 2015, especially among patients with severe pain or on antidepressants, according to a new study.1 The study adds to prior data reporting trends in chronic opioid use in RA patients.2,3 Severe pain was the strongest predictor for use of…
New Study Asks Why Lupus Patients Don’t Take Their Hydroxychloroquine
Hydroxychloroquine (HCQ) therapy may effectively manage systemic lupus erythematosus (SLE) in many patients, but that doesn’t mean patients will take it as often as they should. In fact, results from a recently published study found that about half of SLE patients were not adherent.1 The study was led by Lucy H. Liu, MD, MPH, a…
- « Previous Page
- 1
- …
- 101
- 102
- 103
- 104
- 105
- …
- 331
- Next Page »